On November 2, 2022 PACT Pharma, Inc., a privately held biopharmaceutical company developing transformational personalized neoantigen-specific and off-the-shelf T cell receptor (TCR) T cell therapies for the eradication of solid tumors, reported that new data highlighting its first-of-its-kind adoptive T cell therapy platform will be featured in multiple presentations at the upcoming 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (SITC 2022) (Press release, PACT Pharma, NOV 2, 2022, View Source [SID1234622841]). The company, along with academic research collaborators, will deliver oral and poster presentations, including a late-breaking oral presentation, providing the latest clinical and preclinical findings from its pioneering research in the field of personalized neoantigen TCR T cell therapies. SITC (Free SITC Whitepaper) 2022 is being held November 8-12, 2022, in Boston, Massachusetts.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the company’s presentations at SITC (Free SITC Whitepaper) 2022 are as follows:

Late Breaking Oral Presentation #1478 (With Accompanying Poster):

Title: A Phase I Study of Personalized Adoptive TCR T Cell Therapy in Patients with Solid Tumors: Safety, Efficacy, and T Cell Trafficking to Tumors of Non-virally Gene Edited T Cells
Presenting Author: Stefanie Mandl, Ph.D., chief scientific officer, PACT Pharma
Category/Session: Late Breaking Abstract Session 103
Date/Time: Thursday, November 10, 2022, 11:10 a.m. – 11:40 a.m. Eastern
Location: Hall B2
Oral Presentation #123:

Title: Landscape Analysis of the Neoepitope-specific T Cell Responses in Patients with and without Clinical Benefit from Immune Checkpoint Blockade Therapy
Presenting Author: Cristina Puig Saus, Ph.D., adjunct assistant professor, University of California, Los Angeles
Category/Session: Rapid Oral Abstracts – Basic Science Session 104
Date/Time: Thursday, November 10, 2022, 12:25 – 12:33 p.m. Eastern
Location: 253ABC
Poster Presentation #320:

Title: Rapid Identification of a TCR Library Targeting the HPV E6/E7 Oncoproteins to Enable Multi-TCR T-Cell Therapies for Patients with HPV16+ Epithelial Cancers
Presenting Author: Stefanie Mandl, Ph.D., chief scientific officer, PACT Pharma
Category/Session: Cellular Therapies Poster Session
Date: Friday, November 11, 2022
Location: Poster Hall C
Poster Presentation #712:

Title: Retrospective Tumor Microenvironment Analysis from a Personalized neoTCR-T Cell Therapy Clinical Trial and Its Potential Applications for Off-the-Shelf HPV TCR T Cell therapies
Presenting Author: Chad Smith, Ph.D., associate director, bioinformatics, PACT Pharma
Category/Session: Clinical Trials in Progress Poster Session
Date: Friday, November 11, 2022
Location: Poster Hall C
Additional information on the 37th Annual Meeting of SITC (Free SITC Whitepaper) is available through the conference website at: View Source